Earnings summaries and quarterly performance for Apyx Medical.
Executive leadership at Apyx Medical.
Board of directors at Apyx Medical.
Research analysts who have asked questions during Apyx Medical earnings calls.
Sam Eiber
BTIG, LLC
7 questions for APYX
Also covers: AIRS, EMBC, EOLS +6 more
Matthew Hewitt
Craig-Hallum Capital Group LLC
6 questions for APYX
Also covers: ACET, BHST, BLFS +21 more
Alex Fuhrman
Craig-Hallum Capital Group LLC
2 questions for APYX
Also covers: ATER, BNED, BTMD +21 more
Dave Turkaly
Citizens
2 questions for APYX
Ben Haynor
Lake Street Capital Markets
1 question for APYX
Also covers: ATEC, BFLY, CLGN +6 more
Matthew O'Brien
Piper Sandler & Co.
1 question for APYX
Also covers: ATEC, ATRC, BBNX +18 more
Recent press releases and 8-K filings for APYX.
Apyx Medical Corporation Prices Public Offering of Common Stock
APYX
- Apyx Medical Corporation announced the pricing of its underwritten public offering of 2,762,431 shares of common stock at a public offering price of $3.62 per share.
- The company granted the underwriter, Lucid Capital Markets, a 45-day option to purchase up to an additional 414,365 shares of common stock.
- The offering closed on November 19, 2025, generating approximately $9.4 million in aggregate gross proceeds for the company, before deducting expenses.
- Apyx Medical Corporation intends to use the net proceeds from this offering for working capital and general corporate purposes.
Nov 19, 2025, 9:30 PM
Apyx Medical Reports Strong Q3 2025 Revenue Growth Driven by AYON Launch and Raises Full-Year Guidance
APYX
Earnings
Product Launch
Guidance Update
- Apyx Medical reported Q3 2025 total revenue of $12.9 million, a 12% increase year-over-year, primarily driven by a 19% increase in Surgical Aesthetics revenue to $11.1 million following the commercial launch of the AYON Body Contouring System.
- The company's Advanced Energy segment was officially rebranded to Surgical Aesthetics to better align with its product offerings.
- Net loss attributable to stockholders decreased to $2 million ($0.05 per share) in Q3 2025 from $4.7 million ($0.14 per share) in the prior year, and adjusted EBITDA loss significantly decreased to $0.1 million from $2.4 million, attributed to reduced operating expenses of $9.1 million resulting from cost-cutting measures.
- Apyx Medical updated its full-year 2025 total revenue guidance to a range of $50.5 million-$52.5 million, an increase from the previous range, with Surgical Aesthetics segment revenue guidance also raised to $43 million-$45 million.
- An additional 510(k) application was submitted to the FDA for AYON label expansion to include power liposuction, with clearance anticipated in Q1 2026.
Nov 6, 2025, 1:00 PM
Apyx Medical Reports Q3 2025 Results and Raises Full-Year Guidance
APYX
Earnings
Guidance Update
Product Launch
- Apyx Medical reported total revenue of $12.9 million for the third quarter of 2025, a 12% increase compared to the prior year period, driven by a 19% increase in surgical aesthetics revenue to $11.1 million. This growth was primarily due to the commercial launch of the Aon body contouring system and increased volume of single-use handpieces.
- The company's advanced energy segment has been officially rebranded as Surgical Aesthetics to better align its brand with its mission and products.
- Net loss attributable to stockholders decreased to $2 million ($0.05 per share) in Q3 2025 from $4.7 million ($0.14 per share) in Q3 2024, and adjusted EBITDA loss decreased 96% to $0.1 million, reflecting the positive impact of cost reduction and restructuring efforts initiated in November 2024.
- Apyx Medical updated its full-year 2025 guidance, now expecting total revenue in the range of $50.5 million to $52.5 million, an increase from the previous range, with surgical aesthetics segment revenue projected between $43 million and $45 million.
Nov 6, 2025, 1:00 PM
Apyx Medical Reports Q3 2025 Results, Rebrands Segment, and Updates Full-Year Guidance
APYX
Earnings
Guidance Update
Product Launch
- Apyx Medical reported Q3 2025 total revenue of $12.9 million, a 12% increase year-over-year, primarily driven by a 19% increase in surgical aesthetics revenue to $11.1 million due to the successful commercial launch of the Aon body contouring system.
- The company's net loss significantly decreased to $2 million ($0.05 per share) in Q3 2025 from $4.7 million ($0.14 per share) in the prior year, with adjusted EBITDA loss decreasing to $0.1 million, reflecting effective cost-cutting measures.
- The advanced energy segment was rebranded to surgical aesthetics to better align with the company's focus and the Aon system's capabilities, with an FDA 510(k) submission for Aon's power liposuction label expansion anticipated for Q1 2026 clearance.
- Full-year 2025 revenue guidance was updated to $50.5 million-$52.5 million, an increase from the previous range, with surgical aesthetics revenue guidance also raised to $43 million-$45 million, while OEM revenue guidance was lowered to approximately $7.5 million.
- As of September 30, 2025, cash and cash equivalents were $25.1 million, and cash used in operating activities decreased to $3.5 million for Q3 2025 and $5.5 million for the first nine months of 2025, with projections to yield cash through 2027.
Nov 6, 2025, 1:00 PM
Apyx Medical Corporation Reports Q3 2025 Financial Results and Raises Full-Year Guidance
APYX
Earnings
Guidance Update
Product Launch
- Apyx Medical Corporation reported total revenue of $12.9 million for the third quarter of 2025, an increase from $11.5 million in the comparable prior-year period.
- The company significantly reduced its net loss attributable to stockholders to $2.0 million in Q3 2025, down from $4.7 million in Q3 2024, and its Adjusted EBITDA loss decreased to $0.1 million from $2.4 million.
- Apyx Medical commenced the full U.S. commercial launch of its AYON Body Contouring System™ at the end of Q3 2025, noting demand for pre-orders exceeded expectations.
- The company raised its total revenue guidance for the full year 2025 to a range of $50.5 million to $52.5 million.
Nov 6, 2025, 12:02 PM
Apyx Medical Reports Q3 2025 Financial Results and Raises FY2025 Revenue Guidance
APYX
Earnings
Guidance Update
Product Launch
- Apyx Medical reported total revenue of $12.9 million in the third quarter of 2025, compared to $11.5 million in the comparable period last year.
- The company's net loss attributable to stockholders decreased to $2.0 million in Q3 2025, from $4.7 million in Q3 2024, and Adjusted EBITDA loss decreased 96% to $0.1 million.
- Apyx Medical initiated the full U.S. commercial launch of its AYON Body Contouring System at the end of Q3 2025 and submitted a new 510(k) for AYON label expansion to include power liposuction in October 2025.
- The company increased its total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million, up from the previous guidance of $50.0 million to $52.0 million.
Nov 6, 2025, 12:00 PM
Apyx Medical Corporation Begins Commercial Sales of Apyx One Console
APYX
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Apyx Medical Corporation received approval for its Apyx One Console in May 2025 and commenced commercial selling in Q4 2025.
- The company filed a 510(k) submission for the power-assisted handpiece portion of Apyx One Console, with clearance anticipated in Q1 2026.
- The Apyx One Console is strategically positioned to meet the increasing demand for body contouring solutions, particularly from patients using GLP-1 therapies for weight loss, a market expected to surpass $100 billion by 2030.
- Clinician feedback for the Apyx One Console has been overwhelmingly positive, highlighting its integrated technologies that offer improved efficiency, superior clinical outcomes, and enhanced patient experience.
- The technology is projected to be a direct driver of volume for medical practices, fueled by its efficacy and the growing patient interest in tightening procedures following weight loss.
Oct 14, 2025, 4:00 PM
Apyx Medical Announces AON Body Contouring System Approval and Upward Revenue Guidance
APYX
Guidance Update
Product Launch
New Projects/Investments
- Apyx Medical received FDA approval for its AON body contouring system on May 11, with commercial sales planned to commence in September. This new system aims to consolidate and enhance existing surgical body contouring technologies.
- The company increased its full-year revenue guidance by $2.7 million, now expecting total revenue between $50 million and $52 million for the year. This includes advanced energy revenue of $42 million to $44 million, reflecting approximately 10% growth.
- Apyx Medical is capitalizing on the increased demand for skin tightening due to GLP-1 weight loss drugs, noting 63% of GLP-1 users seek such treatments. Their Renuvion product, the only FDA-approved device for loose and lax skin, saw US handpiece sales grow 14% in 2024, with 93,000 units sold.
- The company is focused on achieving EBITDA positivity by 2026 through cost reductions, with operating costs projected to be less than $40 million in 2025, down from $53 million in 2023. Apyx Medical has approximately $30 million in cash, providing runway through 2027.
Aug 12, 2025, 8:51 PM
Apyx Medical Corporation Launches Renuvion® in China
APYX
Product Launch
New Projects/Investments
- Apyx Medical Corporation launched its Renuvion® product in China as part of its international commercialization strategy.
- The launch followed initial market clearance from the National Medical Products Administration of China.
- Apyx Medical has entered into a distribution agreement with GlamMoon Medical Technology, the equipment distribution division of BeauCare Clinics Investment Co., Ltd. (BCC).
- BCC is a leading platform company in China's medical aesthetics industry, operating over 60 medical aesthetics hospitals and clinics and having a group purchasing alliance with more than 400 alliance members as of Q1 2025.
Jul 28, 2025, 12:08 PM
Apyx Medical Corporation Reports First Quarter 2025 Financial Results
APYX
Earnings
Guidance Update
Product Launch
- Apyx Medical Corporation reported total revenue of $9.4 million in the first quarter of 2025, an 8% decrease compared to $10.2 million in the same period last year. This included a 6% increase in Advanced Energy revenue to $7.9 million and a 45% decrease in OEM revenue to $1.5 million.
- The company significantly reduced its net loss, which decreased by 45% to $4.2 million in Q1 2025 from $7.6 million in Q1 2024. Adjusted EBITDA loss also decreased by 54% to $2.4 million from $5.3 million in the prior year period.
- Apyx Medical reaffirmed its financial guidance for the full year 2025, expecting total revenue in the range of $47.6 million to $49.0 million and operating expenses of less than $40.0 million.
- The company is preparing for the planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearance, and its Renuvion product won the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener".
May 8, 2025, 11:12 AM
Quarterly earnings call transcripts for Apyx Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Apyx Medical's earnings for you
Get instant analysis when filings drop